Target intelligence / Profile preview

Dual-specificity tyrosine-regulated kinase (DYRK)

Target
DYRK
Molecular classification
Enzyme, Protein kinase, Serine-threonine kinase, Tyrosine kinase, CMGC kinase family
01

Overview

The dual-specificity tyrosine-regulated kinases (DYRKs) are a family of protein kinases within the CMGC group, characterized by the ability to phosphorylate substrates on serine/threonine as well as tyrosine residues. Humans encode five known DYRK proteins (DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4), all sharing a highly conserved catalytic core and structural domains specific to their class. DYRK kinases are pleiotropic regulators involved in critical cellular processes, including cell cycle regulation, developmental signaling, gene expression, DNA damage response, and the formation of specialized cellular structures such as the primary cilium. Dysregulation and mutation of these kinases are implicated in various diseases, notably some cancers, neurodevelopmental disorders, and other human pathologies. DYRKs are considered promising but challenging drug targets due to their central roles and the risk of off-target effects.

Other names
DYRK familyDYRK kinasesDual specificity tyrosine-phosphorylation-regulated kinase
02

Mechanism of action

Inhibition of kinase activity (ATP-competitive inhibition), regulation of substrate phosphorylation

03

Biological functions

Signal transductionCell cycle regulationDevelopmental processesCell proliferationCell homeostasisDNA damage responseFormation of primary ciliumRegulation of gene expression
04

Disease associations

CancerNeurodegenerative diseaseDevelopmental disordersOther (such as intellectual disability and Down syndrome, as known from literature)
05

Safety considerations

Off-target toxicity due to kinase cross-reactivitychallenges in specific inhibitor designpotential impact on cell proliferation or neurodevelopment
06

Interacting drugs

Known drugs include multi-kinase inhibitors (such as harmine, which targets DYRK1A), but no very specific FDA-approved drugs for any DYRK exist as of 2024
07

Biomarkers

DYRK1A protein expression (for Down syndrome and some cancers)gene amplification or mutation status (studied for research; not established as routine clinical biomarkers)

Beyond the preview

Go deeper on Dual-specificity tyrosine-regulated kinase (DYRK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dual-specificity tyrosine-regulated kinase (DYRK).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call